Medtronic has announced three US milestones expanding access to its MiniMed 780G automated insulin delivery system.
The company has announced Medicare access for its MiniMed 780G, paired with the Instinct sensor made by Abbott, FDA clearance for the pairing for insulin-requiring Type 2 diabetes, as well as FDA clearance for the system’s use with ultra rapid-acting insulins.
Medtronic and Abbott entered into a collaboration in August 2024 to pair insulin delivery and continuous glucose monitoring (CGM) technologies. Medtronic launched the MiniMed 780G with the Instinct sensor made by Abbott late 2025.
MiniMed 780G, the company’s latest-generation AID system, offers meal detection technology and provides automatic adjustments and corrections to sugar levels every five minutes. This occurs for both basal (background) and bolus (mealtime) insulin needs. The algorithm auto-corrects glucose levels to provide support for missed boluses or underestimated carbohydrates.
“These milestones reflect our unwavering commitment to expanding access and giving individuals living with diabetes more choice in how they manage their condition,” said Que Dallara, EVP & President, Medtronic Diabetes. “By broadening sensor and insulin options for the MiniMed 780G system, we’re empowering more people to benefit from automated insulin delivery that supports easier mealtimes, greater flexibility, and more confident diabetes management—making everyday life a bit easier.”
To find out more, CLICK HERE.
